Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Sanofi India Ltd. Share Price
Day's Range
Day's Range
Low
₹3,258.10
High
₹3,306.60
Price Summary
| Previous Close | ₹3,285.10 |
|---|---|
| Day's Range | ₹3,258.10 - ₹3,306.60 |
| Open | ₹3,299.00 |
| 52 Week Range | ₹3,054.00 - ₹5,291.00 |
| Volume | 12,153 |
| Market Cap | ₹0.01 |
| Previous Close | ₹3,298.95 |
|---|---|
| Day's Range | ₹3,263.75 - ₹3,301.70 |
| Open | ₹3,280.55 |
| 52 Week Range | ₹3,057.60 - ₹5,286.45 |
| Volume | 553 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 399.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 3.76 |
| Price/Earning (TTM) | 18.24 |
| TTM EPS (₹) | 179.46 |
| P/E Ratio | 34.06 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 15.20 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.16 |
| Trade Value ( ₹ in Lacs) | 18.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 3.76 |
| Price/Earning (TTM) | 18.24 |
| TTM EPS (₹) | 179.46 |
| P/E Ratio | 34.06 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 15.20 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.16 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4063.0 | 20132.0 |
| Expenses | N/A | N/A |
| PBT | 941.0 | 4314.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 695.0 | 4135.0 |
About Sanofi India Ltd.
| Founded | 1956 |
|---|---|
| Managing Director | Deepak Arora |
| NSE Symbol | SANOFI |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,55,393.78 | 1,901.75 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,26,311.96 | 8,581.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,678.41 | 5,007.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,516.12 | 8,695.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,392.01 | 1,437.60 | 1,165.70 - 1,165.70 |
| Lenskart Solutions Ltd. | 1,11,193.84 | 647.35 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,10,224.17 | 1,108.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,01,506.15 | 2,219.40 | 1,875.00 - 1,875.00 |
| Mankind Pharma Ltd. | 98,747.34 | 2,398.00 | 1,909.70 - 1,909.70 |
| Manipal Health Enterprises Ltd. | 97,936.41 | 729.20 | 625.45 - 625.45 |
No Records Found
Latest News
Sanofi India informs about analyst meet
Sanofi India informs about resignation of director
Pursuant to Regulation 30 of the Listing Regulations, Sanofi India has informed that Rachid Ayari (DIN:10408699) vide his letter dated 22nd July 2026, had conveyed his decision to step down from his current role as the Whole Time Director, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 30th September 2026, in view of his transition to another role within the Sanofi group. Accordingly, Rachid Ayari shall cease to be the Whole Time Director, Chief Financial Officer, Key Managerial Personnel and shall also cease to be Senior Management Personnel and member of the Risk Management Committee effective from the close of business hours on 30th September 2026. The Company places on record its sincere appreciation to Rachid Ayari for his valuable contributions, expert guidance, and dedicated assistance provided during his tenure with the Company. The Company is in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as a Key Managerial Personnel. The Company will inform the Stock Exchanges of the appointment in due course. The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as ‘Annexure-I’ and letter received from Rachid Ayari is enclosed as ‘Annexure – II’.
Sanofi India submits board meeting intimation
Beryl Drugs informs about disclosure
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Glenmark) today announced the receipt of U.S. FDA approval1 for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. Glenmark’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase®2 Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121] and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Sanofi India Ltd. is ₹3,285.10 as of 2026-08-20.
The market capitalisation of Sanofi India Ltd. is ₹7,540.11 as of 2026-08-19.
The 1-year return of Sanofi India Ltd. is -1,888.90% as of 2026-08-20.
The P/E ratio of Sanofi India Ltd. is 28.81 as of 2026-08-20.
The 52-week high and low of Sanofi India Ltd. are ₹5,291.00 and ₹3,054.00, respectively, as of 2026-08-20.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
